What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?

Abbie S. Ornelas, Alyx B Porter Umphrey, Akanksha Sharma, Molly G. Knox, Lisa A. Marks, Dean Marko Wingerchuk, Cumara B. O'Carroll

Research output: Contribution to journalArticle

Abstract

Alternating electrical fields can disrupt mitosis leading to apoptosis of rapidly dividing cancer cells. The device that utilizes this mechanism is known as tumor-treating fields (TTFields). TTFields can be applied by ceramic transducer arrays on a shaved scalp to deliver the alternating electric activity to patients with glioblastoma (GBM). It has FDA approval for use in both recurrent and newly diagnosed GBM. The objective is to critically appraise the current evidence for the use of TTFields as adjunctive treatment to newly diagnosed GBM. The objective was addressed through the development of a structured, critically appraised topic. We incorporated a clinical scenario, background information, a structured question, literature search strategy, evidence summary, clinical bottom lines, and expert discussion. Participants included consultant and resident neurologists, a medical librarian, clinical epidemiologists, and content experts in the field of neurooncology. A randomized controlled trial was selected for critical appraisal. Patients with newly diagnosed GBM completing standard radiation and chemotherapy with temozolomide (TMZ) were subsequently randomized to receive maintenance TMZ with TTFields, or TMZ alone. With the addition of TTFields, median progression-free survival was 6.7 months compared with 4 months without the addition of TTFields (95% confidence interval, 0.52-0.76; P<0.001) and overall survival was 20.9 months compared with 16.0 months without the addition of TTFields (95% confidence interval, 0.53-0.76; P<0.001). TTFields may increase both progression-free and overall survival in patients receiving standard chemoradiation therapy for GBM.

Original languageEnglish (US)
Pages (from-to)71-73
Number of pages3
JournalThe neurologist
Volume24
Issue number2
DOIs
StatePublished - Mar 1 2019
Externally publishedYes

Fingerprint

Glioblastoma
temozolomide
Neoplasms
Disease-Free Survival
Confidence Intervals
Librarians
Ceramics
Consultants
Scalp
Transducers
Mitosis
Randomized Controlled Trials
Maintenance
Radiation
Apoptosis
Drug Therapy
Equipment and Supplies
Survival
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma? / Ornelas, Abbie S.; Porter Umphrey, Alyx B; Sharma, Akanksha; Knox, Molly G.; Marks, Lisa A.; Wingerchuk, Dean Marko; O'Carroll, Cumara B.

In: The neurologist, Vol. 24, No. 2, 01.03.2019, p. 71-73.

Research output: Contribution to journalArticle

Ornelas, Abbie S. ; Porter Umphrey, Alyx B ; Sharma, Akanksha ; Knox, Molly G. ; Marks, Lisa A. ; Wingerchuk, Dean Marko ; O'Carroll, Cumara B. / What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?. In: The neurologist. 2019 ; Vol. 24, No. 2. pp. 71-73.
@article{f75eea567c7048c595d1835ae19798ac,
title = "What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?",
abstract = "Alternating electrical fields can disrupt mitosis leading to apoptosis of rapidly dividing cancer cells. The device that utilizes this mechanism is known as tumor-treating fields (TTFields). TTFields can be applied by ceramic transducer arrays on a shaved scalp to deliver the alternating electric activity to patients with glioblastoma (GBM). It has FDA approval for use in both recurrent and newly diagnosed GBM. The objective is to critically appraise the current evidence for the use of TTFields as adjunctive treatment to newly diagnosed GBM. The objective was addressed through the development of a structured, critically appraised topic. We incorporated a clinical scenario, background information, a structured question, literature search strategy, evidence summary, clinical bottom lines, and expert discussion. Participants included consultant and resident neurologists, a medical librarian, clinical epidemiologists, and content experts in the field of neurooncology. A randomized controlled trial was selected for critical appraisal. Patients with newly diagnosed GBM completing standard radiation and chemotherapy with temozolomide (TMZ) were subsequently randomized to receive maintenance TMZ with TTFields, or TMZ alone. With the addition of TTFields, median progression-free survival was 6.7 months compared with 4 months without the addition of TTFields (95{\%} confidence interval, 0.52-0.76; P<0.001) and overall survival was 20.9 months compared with 16.0 months without the addition of TTFields (95{\%} confidence interval, 0.53-0.76; P<0.001). TTFields may increase both progression-free and overall survival in patients receiving standard chemoradiation therapy for GBM.",
author = "Ornelas, {Abbie S.} and {Porter Umphrey}, {Alyx B} and Akanksha Sharma and Knox, {Molly G.} and Marks, {Lisa A.} and Wingerchuk, {Dean Marko} and O'Carroll, {Cumara B.}",
year = "2019",
month = "3",
day = "1",
doi = "10.1097/NRL.0000000000000222",
language = "English (US)",
volume = "24",
pages = "71--73",
journal = "Neurologist",
issn = "1074-7931",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?

AU - Ornelas, Abbie S.

AU - Porter Umphrey, Alyx B

AU - Sharma, Akanksha

AU - Knox, Molly G.

AU - Marks, Lisa A.

AU - Wingerchuk, Dean Marko

AU - O'Carroll, Cumara B.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Alternating electrical fields can disrupt mitosis leading to apoptosis of rapidly dividing cancer cells. The device that utilizes this mechanism is known as tumor-treating fields (TTFields). TTFields can be applied by ceramic transducer arrays on a shaved scalp to deliver the alternating electric activity to patients with glioblastoma (GBM). It has FDA approval for use in both recurrent and newly diagnosed GBM. The objective is to critically appraise the current evidence for the use of TTFields as adjunctive treatment to newly diagnosed GBM. The objective was addressed through the development of a structured, critically appraised topic. We incorporated a clinical scenario, background information, a structured question, literature search strategy, evidence summary, clinical bottom lines, and expert discussion. Participants included consultant and resident neurologists, a medical librarian, clinical epidemiologists, and content experts in the field of neurooncology. A randomized controlled trial was selected for critical appraisal. Patients with newly diagnosed GBM completing standard radiation and chemotherapy with temozolomide (TMZ) were subsequently randomized to receive maintenance TMZ with TTFields, or TMZ alone. With the addition of TTFields, median progression-free survival was 6.7 months compared with 4 months without the addition of TTFields (95% confidence interval, 0.52-0.76; P<0.001) and overall survival was 20.9 months compared with 16.0 months without the addition of TTFields (95% confidence interval, 0.53-0.76; P<0.001). TTFields may increase both progression-free and overall survival in patients receiving standard chemoradiation therapy for GBM.

AB - Alternating electrical fields can disrupt mitosis leading to apoptosis of rapidly dividing cancer cells. The device that utilizes this mechanism is known as tumor-treating fields (TTFields). TTFields can be applied by ceramic transducer arrays on a shaved scalp to deliver the alternating electric activity to patients with glioblastoma (GBM). It has FDA approval for use in both recurrent and newly diagnosed GBM. The objective is to critically appraise the current evidence for the use of TTFields as adjunctive treatment to newly diagnosed GBM. The objective was addressed through the development of a structured, critically appraised topic. We incorporated a clinical scenario, background information, a structured question, literature search strategy, evidence summary, clinical bottom lines, and expert discussion. Participants included consultant and resident neurologists, a medical librarian, clinical epidemiologists, and content experts in the field of neurooncology. A randomized controlled trial was selected for critical appraisal. Patients with newly diagnosed GBM completing standard radiation and chemotherapy with temozolomide (TMZ) were subsequently randomized to receive maintenance TMZ with TTFields, or TMZ alone. With the addition of TTFields, median progression-free survival was 6.7 months compared with 4 months without the addition of TTFields (95% confidence interval, 0.52-0.76; P<0.001) and overall survival was 20.9 months compared with 16.0 months without the addition of TTFields (95% confidence interval, 0.53-0.76; P<0.001). TTFields may increase both progression-free and overall survival in patients receiving standard chemoradiation therapy for GBM.

UR - http://www.scopus.com/inward/record.url?scp=85062395789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062395789&partnerID=8YFLogxK

U2 - 10.1097/NRL.0000000000000222

DO - 10.1097/NRL.0000000000000222

M3 - Article

VL - 24

SP - 71

EP - 73

JO - Neurologist

JF - Neurologist

SN - 1074-7931

IS - 2

ER -